94 related articles for article (PubMed ID: 16962036)
1. [KIR3DL2: a new step for the management of patients with Sezary syndrome].
Ortonne N; Bagot M; Bensussan A
Med Sci (Paris); 2006; 22(8-9):691-3. PubMed ID: 16962036
[No Abstract] [Full Text] [Related]
2. [Item no 164: malignant lymphoma: cutaneous lymphoma].
CEDEF
Ann Dermatol Venereol; 2008 Nov; 135(11 Suppl):F160-2. PubMed ID: 18984207
[No Abstract] [Full Text] [Related]
3. Management of cutaneous T-cell lymphoma: The future is here.
Wood GS
J Am Acad Dermatol; 2001 Aug; 45(2):317. PubMed ID: 11464201
[No Abstract] [Full Text] [Related]
4. New options in diagnosis and management of mycosis fungoides and Sézary syndrome.
Enke CA
Oncology (Williston Park); 2010 May; 24(6):507-8. PubMed ID: 20568591
[No Abstract] [Full Text] [Related]
5. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and immunological characteristics of erythrodermal lymphomas of the skin].
Shaposhnikov OK; Rodionov AN; Karachunova TN
Vestn Dermatol Venerol; 1985 Jan; (1):4-9. PubMed ID: 3156460
[No Abstract] [Full Text] [Related]
7. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
8. From single-cell signature to prognostic factors: the case of Sézary syndrome.
Scala E; Narducci MG; Russo G
Expert Rev Clin Immunol; 2012 Nov; 8(8):699-701. PubMed ID: 23167680
[No Abstract] [Full Text] [Related]
9. Sézary syndrome: a summary.
Bouwhuis S; Davis MD
Dermatol Nurs; 2001 Jun; 13(3):205-7, 230. PubMed ID: 11917454
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic eosinophilia.
Guitart J
N Engl J Med; 2000 Mar; 342(9):659-60; author reply 660-1. PubMed ID: 10702057
[No Abstract] [Full Text] [Related]
11. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotyping of Sézary cells.
Russell-Jones R
Br J Dermatol; 2001 Jan; 144(1):2-3. PubMed ID: 11167675
[No Abstract] [Full Text] [Related]
13. Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.
Spicknall KE
Semin Cutan Med Surg; 2018 Mar; 37(1):18-23. PubMed ID: 29719016
[TBL] [Abstract][Full Text] [Related]
14. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
[No Abstract] [Full Text] [Related]
15. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
Introcaso CE; Hess SD; Kamoun M; Ubriani R; Gelfand JM; Rook AH
J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
[TBL] [Abstract][Full Text] [Related]
16. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
[TBL] [Abstract][Full Text] [Related]
17. Phenotype of cells involved in mycosis fungoides and Sézary syndrome (blood and skin lesions): immunomorphological study with monoclonal antibodies.
Schmitt D; Souteyrand P; Brochier J; Czernielewski J; Thivolet J
Acta Derm Venereol; 1982; 62(3):193-9. PubMed ID: 6179357
[TBL] [Abstract][Full Text] [Related]
18. Circulating Sézary cells. A new preparatory method for their identification and enumeration.
Fletcher V; Zackheim HS; Beckstead JH
Arch Pathol Lab Med; 1984 Dec; 108(12):954-8. PubMed ID: 6239604
[TBL] [Abstract][Full Text] [Related]
19. Sezary syndrome: a case report and a review of the molecular pathomechanism and management.
Ng PP; Goh CL
Ann Acad Med Singap; 1998 Nov; 27(6):864-7. PubMed ID: 10101566
[TBL] [Abstract][Full Text] [Related]
20. Rapid progression of immune dysregulation in an HIV-infected patient with Sézary syndrome.
Dadoo AS; Steenkamp I
Dermatol Online J; 2019 Jan; 25(1):. PubMed ID: 30710903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
